AARHUS UNIVERSITY

Coversheet

This is the accepted manuscript (post-print version) of the article.

Contentwise, the post-print version is identical to the final published version, but there may be differences in typography and layout.

How to cite this publication

Please cite the final published version:

Farver-Vestergaard, I., Jacobsen, D. Ø., & Zachariae, R. (2015). Efficacy of psychosocial interventions on psychological and physical health outcomes in chronic obstructive pulmonary disease: A systematic review and meta-analysis. *Psychotherapy and Psychosomatics*, 84(1), 37-50. DOI: [10.1159/000367635](https://doi.org/10.1159/000367635)

Publication metadata

Title:	<i>Efficacy of psychosocial interventions on psychological and physical health outcomes in chronic obstructive pulmonary disease: A systematic review and meta-analysis</i>
Author(s):	<i>Ingeborg Farver-Vestergaard, Dorte Jacobsen & Robert Zachariae</i>
Journal:	<i>Psychotherapy and Psychosomatics</i>
DOI/Link:	10.1159/000367635
Document version:	Accepted manuscript (post-print)

General Rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

1 Short/running title: PSYCHOSOCIAL INTERVENTIONS IN COPD

2

3 **TITLE PAGE**

4

5 **Efficacy of psychosocial interventions on psychological and physical health outcomes in**
6 **chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis**

7

8 **I. Farver-Vestergaard, D. Jacobsen, R. Zachariae**

9 *Unit for Psychooncology and Health Psychology, Dept. of Oncology, Aarhus University Hospital*
10 *and Dept. of Psychology and Behavioral Science, Aarhus University, Aarhus C, Denmark*

11

12

13 Abstract: 198 words

14 Main text body (excl. abstract, references, figures, and tables): 4420 words

15

16 **Key-words:** Meta-analysis, psychosocial intervention, chronic disease management, chronic ob-
17 structive pulmonary disease

18

19

20

21

22

23

24 **Corresponding author:** Ingeborg Farver-Vestergaard, MSc., PhD.stud., Unit for Psychooncology
25 and Health Psychology, Dept of Oncology, Aarhus University Hospital and Dept of Psychology,
26 Aarhus University, Bartholins Allé 9; Bld. 1340; DK8000 Aarhus C, Denmark, Phone: +45 8716
27 6154, e-mail: ifarver@psy.au.dk

28

29 **ABSTRACT**

30 *Background:* Psychosocial intervention has been suggested as a potentially effective supplement to
31 medical treatment in COPD, but no reviews so far have quantified the existing research in terms of
32 both psychological and physical health outcomes. We therefore conducted a systematic review and
33 meta-analysis of controlled trials evaluating the effects of psychosocial interventions on psycholog-
34 ical and physical health outcomes in COPD.

35 *Methods:* Two independent raters screened 1491 references for eligibility. Twenty independent
36 studies investigating a total of 1361 patients were included, assessed for their methodological quali-
37 ty, and subjected to meta-analytic evaluation.

38 *Results:* After adjusting for potential publication bias, a statistically significant overall effect was
39 found for psychological (Hedges' $g=0.39$, 95% CI: 0.19-0.58; $p<0.001$) outcomes. When analyzing
40 individual intervention types, CBT appeared to be effective ($g=0.39$, CI: 0.15-0.62; $p=0.001$) for
41 improving psychological outcomes. In contrast, for physical outcomes, only mind-body interven-
42 tions (e.g. mindfulness-based therapy, yoga, and relaxation) revealed a statistically significant effect
43 ($g=0.40$; CI: 0.01-0.79; $p=0.042$).

44 *Conclusions:* Taken together, the results lend support to psychosocial intervention as a tool in the
45 management of COPD. However, due to indications of possible publication bias towards positive
46 findings, the results should be interpreted with some caution, and more high quality research is
47 needed.

48

49

50

51 INTRODUCTION

52 Chronic obstructive pulmonary disease (COPD) involves persistent obstruction of the airways and
53 lung function impairment, and it affects up to about 10% of the population worldwide [1]. The most
54 common physical symptoms of the disease are breathlessness (dyspnea), cough, and excessive spu-
55 tum production [2], but many patients also experience extrapulmonary physical consequences such
56 as systemic inflammation, nutritional abnormalities, and musculoskeletal dysfunction, resulting in
57 fatigue, low activity level, and poor exercise capacity [3]. In addition to these devastating physical
58 problems, patients with COPD often experience psychological problems in the form of symptoms
59 of anxiety and depression [4]. In the research literature, these symptoms are often combined as spe-
60 cific components of overall psychological distress or psychological impairment [5–7]. Furthermore,
61 adding to the confusion, several studies focus on poor health-related quality of life (QoL), which is
62 a multi-faceted construct including both physical, psychological, and social function and symptoms
63 [8]. The physical and psychological effects of the disease appear to influence each other significant-
64 ly, as exemplified by research reporting links between fatigue and QoL [9], psychological distress
65 and exacerbation rates [5], as well as dyspnea and anxiety and depression [10–12]. Psychosocial
66 intervention, defined as intervention programs with a psychosocial aim that does not include the
67 prescription of medications or has a solely physical focus (e.g. acupuncture or massage therapy),
68 could therefore serve as a potentially effective supplement to medical or physically oriented treat-
69 ment initiatives in COPD.

70 So far, a number of reviews have summarized the effects of psychosocial interventions on psycho-
71 logical outcomes in COPD. In 2002, Rose and colleagues [13] published a narrative systematic re-
72 view of six randomized controlled trials (RCTs) evaluating psychological interventions as a means
73 of reducing anxiety and panic, and concluded that the evidence in the area was inconclusive. Later,
74 Coventry and Gellatly [14] conducted a systematic review of four studies of cognitive behavioral

75 therapy (CBT) for COPD patients with mild-to-moderate anxiety and depression. They included
76 non-randomized (NRCT) as well as RCTs, but found no conclusive evidence of an effect. More
77 recently, in a comprehensive systematic review and meta-analysis of 9 studies (RCTs as well as
78 non-controlled studies) by Baraniak and Sheffield [15], the authors noted that psychologically ori-
79 ented interventions often included aims of improving physical outcomes such as physical function-
80 ing, dyspnea and exercise capacity. Despite this, their subsequent meta-analysis only included the
81 psychological outcomes of anxiety, depression, and QoL. Their analysis revealed a medium com-
82 bined effect size ($r = -0.273$, CI -0.419 to -0.141) on anxiety only, corresponding to a standardized
83 mean difference (Cohen's d) of 0.57. Clark and colleagues [16] have contributed with a broader
84 narrative review of non-systematic reviews, systematic reviews, and meta-analyses that included
85 clinical and educational as well as psychosocial interventions. They concluded that behaviorally
86 oriented interventions, in addition to improving psychological outcomes, also have the potential of
87 influencing physical outcomes such as pulmonary function and exercise capacity, but did not further
88 address the efficacy of psychosocial interventions on psychological and physical outcomes. Fur-
89 thermore, the available reviews generally note the relatively low methodological quality of studies
90 evaluating psychosocial interventions in COPD.

91 To the best of our knowledge, there has thus not yet been an attempt to systematically and quantita-
92 tively evaluate psychosocial interventions in terms of both psychological and physical outcomes in
93 COPD. The objective of the present study was therefore to contribute to the evidence base by con-
94 ducting a systematic review and meta-analysis of the efficacy of psychosocial interventions on rele-
95 vant psychological as well as physical outcomes in COPD. In addition, it was explored whether
96 some types of psychosocial interventions (e.g. CBT that focuses on altering maladaptive links be-
97 tween thinking and behavior patterns [17] or mind-body interventions that focus on the bidirectional
98 relationship of mind and body as the mediator of change such as for example mindfulness-based

99 therapy, meditative yoga or relaxation [18]) are more effective than other and to what degree the
100 effects are related to the methodological quality of the studies.

101 **METHODS**

102 The present study was protocol-based and conducted in accordance with the PICO-approach [19]
103 and the PRISMA recommendations for reporting systematic reviews and meta-analyses [20].

104 *Search strategy*

105 We conducted a systematic review using a keyword-based search in the electronic databases of
106 PubMed, PsychINFO, Embase, Web of Science, Cochrane Library and CINAHL. Relevant MeSH
107 terms of all databases were included in the search. Keywords related to the population (COPD OR
108 “chronic obstructive pulmonary disease” OR “chronic obstructive lung disease” OR “chronic ob-
109 structive airway disease” OR “chronic obstructive respiratory disease” OR “chronic bronchitis” OR
110 emphysema) were combined with keywords related to the intervention (“psychological interven-
111 tion*” OR “psychosocial intervention*” OR psychotherap* OR psychoeducation* OR psycho-
112 education* OR “behavi*ral therap*” OR “cognitive therap*” OR mindfulness* OR relaxation* OR
113 meditation OR imagery OR hypnos*) and outcomes (depressi* OR anxiet* OR panic OR “quality
114 of life” OR “mental health” OR “health status” OR “physical activity” OR exercise OR “pulmonary
115 function” OR “lung function” OR “symptom level” OR breathlessness OR dyspnea OR fatigue).
116 The search was conducted independently by the first and the second author (IF and DJ) for the peri-
117 od from database inception to March 2014.

118 *Selection procedure and data extraction*

119 Only English-language reports published in peer-reviewed journals were considered eligible for the
120 present study. Eligible studies were those that evaluated individual-, or group-based psychosocial
121 interventions aimed at improving psychological and/or physical outcomes for adult patients with a

122 COPD diagnosis. Concerning study design and comparison, only trials with a control group were
123 included. Papers were excluded if the focus was on patients with comorbid physical conditions or if
124 the intervention did not involve a psychosocial component. For example, interventions in the form
125 of pulmonary rehabilitation or self-management programs were excluded unless a substantial part of
126 the program was explicitly characterized as being psychosocial, e.g. mind-body exercises such as
127 meditative yoga, or counseling with elements of CBT or analytical therapy. In addition, reports fo-
128 cusing on interventions with a physical focus, such as acupuncture or massage therapy, or on com-
129plementary and alternative treatments, e.g. energy healing or music therapy, were generally exclud-
130ed. However, certain complementary and alternative interventions were included if they primarily
131consisted of psychosocial components that had a broader biopsychosocial purpose, e.g. relaxation,
132guided imagery or meditation.

133 In the first round of assessment, the authors IF and DJ independently removed duplicates and
134 screened the titles and abstracts of the identified references with the purpose of excluding irrelevant
135 studies. In the second round of assessment, full-texts of the remaining references were read and
136 ineligible reports were excluded on the basis of the criteria describe above and the reasons for ex-
137clusion registered. Disagreements and uncertainties were discussed with the third author (RZ) until
138a negotiated conclusion was reached.

139 Using the Microsoft Access software, a database was designed with the specific purpose of manag-
140ing the data of the present study. Data from the included studies were extracted independently and
141cross-checked by IF and DJ. Any disagreements were resolved by negotiation with RZ. When there
142was disagreement on one or more of the criteria included in the quality assessment, the paper was
143re-examined closely, the initial reason for disagreement discussed, and a negotiated conclusion
144reached.

145 *Quality assessment*

146 Study quality was assessed using the Jadad criteria [21], a tool to evaluate methodological quality,
147 e.g. use and description of randomization- and blinding procedures and description of dropout rates
148 (score range: 0-13). Five additional quality criteria were specifically developed for the present study
149 (inclusion of an active control group, pre-post data, any attempts of blinding of patients and/or re-
150 searchers, use of standardized and reliable outcome measures), yielding a revised Jadad total quality
151 score (range: 0-18). Quality ratings were not used as weights when calculating aggregated effect
152 sizes (ES's), as this is discouraged due to risk of inducing bias [22]. Instead, associations between
153 ES's and study quality were explored with meta-ANOVAs and meta-regression.

154 *Heterogeneity*

155 Heterogeneity was explored using Q and I^2 statistics. Heterogeneity tests are aimed at determining
156 whether results reflect genuine between-study differences (heterogeneity), or whether the variation
157 is due to random error (homogeneity) [23]. Due to the generally low statistical power of heterogene-
158 ity tests, a p -value ≤ 0.10 was used to determine significant heterogeneity [24]. The I^2 quantity pro-
159 vides a measure of the degree of inconsistency by estimating the amount of variance in a pooled ES
160 that can be accounted for by heterogeneity in the sample of studies and is not influenced by the
161 number of studies (K) [25]. An I^2 value of 0% indicates no observed heterogeneity. Values of 25%,
162 50%, and 75% are considered low, moderate, and high, respectively.

163 *Computing effect sizes*

164 Hedges' g was used as the standardized effect size. Hedges' g is a variation of Cohen's d [26] cor-
165 recting for possible bias due to small sample size [27]. They both provide an estimate of the stand-
166 ardized mean difference, but whereas d pools the variances using n for each sample, g uses $n-1$ for
167 each sample. ES's were computed using pre- and post-intervention means or medians and their
168 standard deviations or ranges. In case of missing data, we attempted to contact the authors, asking

169 them to provide this information. Pooled ES's were weighted by the inverse standard error, taking
170 into account the precision of each study. A random effects model was used in all analyses. For
171 readers more familiar with r (the effect size correlation) as an indicator of effect, the corresponding
172 r has also been included in the text.

173 ***Analytical strategy***

174 First, pooled overall ES's for the effect of psychosocial interventions on psychological and physical
175 outcomes were calculated. If the results indicated study heterogeneity, possible between-study dif-
176 ferences in ES's were explored by comparing the ES's of studies according to the following study
177 characteristics: active versus passive control, intervention type, methodological quality, treatment
178 duration, number of sessions, age, gender, and lung function at baseline. This was done with either
179 meta-ANOVA or meta-regression.

180 The calculations were conducted with Comprehensive Meta-Analysis, Version 2 ([www.meta-](http://www.meta-analysis.com)
181 [analysis.com](http://www.meta-analysis.com)), SPSS-20 (www.ibm.com/software/analytics/spss/), and various formulas in Mi-
182 crosoft Excel.

183 ***Publication bias***

184 Publication bias, a widespread problem when conducting meta-analyses [28], was evaluated with
185 funnel plots, Egger's method, and by calculating fail-safe numbers [29,30]. A funnel plot is a graph-
186 ic illustration of study ES's in relation to study size or precision. Egger's test provides a statistic for
187 the skewness of results [31]. Calculation of fail-safe numbers is aimed at achieving an indication of
188 the number of unpublished studies with null-findings that would reduce the result to statistical non-
189 significance ($p > 0.05$). It has been suggested that a reasonable level is achieved if the fail-safe num-
190 ber exceeds $5K+10$ ($K = N$ studies in the meta-analysis) [32]. If the results were suggestive of pub-

191 lication bias, an adjusted ES was calculated using Duval and Tweedie's trim and fill method [33],
192 which imputes ES's of missing studies and recalculates the ES accordingly.

193 **RESULTS**

194 The study selection process with reasons for exclusion is described in the PRISMA flow diagram
195 shown in [Figure 1](#). The initial search yielded 1491 articles, out of which 403 articles were read in
196 full during the second round of assessment. The authors IF and DJ initially disagreed on 102 (25%)
197 articles (inter-rater agreement: 0.50 (Kappa statistic)). Keeping in mind the broad and complex na-
198 ture of the field of behavioral intervention, disagreements were most often a result of different ini-
199 tial assumptions of whether certain complex behavioral interventions could be classified as psycho-
200 social intervention. The specific criteria and final inclusion of the individual studies were thus nego-
201 tiated, and the third author, RZ, took part in the discussion concerning 58 of the articles selected in
202 the first round. After excluding further 41 articles, 3 additional articles were included on the basis of
203 a screening of other systematic reviews on the subject [13–15]. The authors of two papers with
204 missing data (control group data and SDs, respectively) provided the requested data after they were
205 contacted. The author of a third paper with missing data (means and SD for all outcomes relevant
206 for the purpose of the present study) was unable to provide the data and the study was therefore
207 excluded. A final total of 20 individual research papers describing results of 20 independent studies
208 published from 1983 to 2012 were included in the study and subjected to meta-analytic evaluation.

209 *Study characteristics*

210 The characteristics of the included studies are summarized in [Table 1](#). The 20 studies had investi-
211 gated a total of 1565 COPD-patients (mean % women: 35.1) and analyzed final data for 1361 par-
212 ticipants. Six-hundred-eighty-three subjects received psychosocial intervention, 394 took part in an
213 intervention that could not be classified as psychosocial (active control group), and 284 received
214 care as usual (passive control group). Mean age ranged from 56.4 to 73.4 years and mean baseline

215 lung function varied from 34.0 to 60.5% predicted forced expiratory volume per second (FEV1% pred.).
216 Study sample sizes ranged from 10 to 238 (mean N: 78.2). A total of 19 studies were RCTs with the
217 remaining study presenting data from a NRCT. The majority of interventions could be classified as
218 either CBT (10 studies) or mind-body interventions (8 studies) (e.g. mindfulness-based therapy,
219 yoga, and relaxation). The two remaining interventions were analytical and behavioral therapy, re-
220 spectively. The number of treatment sessions varied from 1 to 63 (mean: 12.0 sessions) and
221 stretched over 1 to 12 weeks (mean: 7.3 weeks).

222 Three studies [34–36] included more than two group conditions, and data from conditions that made
223 it impossible to isolate the effect of the psychosocial intervention (e.g. comprehensive pulmonary
224 rehabilitation programs with psychosocial elements) were excluded. One study [37] included both
225 an active and a passive control group, and only the active group was used as comparison.

226 Across the included studies, 14 studies reported data on the psychological outcomes of anxiety and
227 depression, frequently assessed in parallel by the Hospital Anxiety and Depression Scale (HADS)
228 or separately by the Spielberger Anxiety Inventory (SAI) or Beck Anxiety Inventory (BAI) to
229 measure anxiety, and the Beck Depression Inventory (BDI) or the Center for Epidemiological Stud-
230 ies Depression (CES-D) scale to measure depression. Seventeen studies reported data on physical
231 health outcomes such as lung function, dyspnea, exercise capacity and fatigue, most often assessed
232 with spirometry (FEV1), visual analogue scales (VAS), the 6-Minutes Walking Test (6MWT), and
233 the Pittsburgh Sleep Quality Index (PSQI), respectively. Sixteen studies reported data on QoL, most
234 often measured with the disease-specific Saint George's Respiratory Questionnaire (SGRQ), the
235 Chronic Respiratory Questionnaire (CRQ), or the generic instrument Short Form Health Survey
236 (SF-36).

237 The Jadad quality score of the included studies ranged from 5-11 (mean score: 9.00; SD: 1.65), and
238 the Jadad-revised score from 7-15 (mean score: 11.95; SD: 2.09). The inter-rater agreement ratio for
239 the individual Jadad items ranged from 0.70 to 1 with Kappa scores (adjusting for chance agree-
240 ment) ranging from 0.32 to 0.80.

241 ***Pooled ESs***

242 The results of the meta-analyses are summarized in [Table 2](#) and illustrated with Forrest plots ([Fig-](#)
243 [ure 2](#)). As the QoL construct includes both psychological and physical domains, a combined ES for
244 QoL was calculated separately. Combining the ES's in the two overall categories of psychological
245 and physical outcomes, regardless of individual study characteristics, yielded statistically significant
246 ES's for both categories (psychological: Hedges' $g=0.39$ (corresponding to $r=0.19$), $p<0.001$; phys-
247 ical: $g=0.30$ ($r=0.15$), $p=0.006$), in both cases corresponding to a small effect [26]. The fail-safe
248 number for psychological outcomes ($K=90$) exceeded the criterion ($K=80$) [32], suggesting a robust
249 effect. This was not the case for the physical outcomes fail-safe number ($K=64$; criterion $K=95$).
250 When exploring indicators of publication bias, the funnel plots for both outcome categories ap-
251 peared skewed and Egger's test indicated the possibility of bias in favor of larger published positive
252 ES's. When imputing missing ES's with the trim and fill method [33], the resulting adjusted pooled
253 ES was smaller but remained statistically significant for the psychological outcome category. This
254 was not the case for physical outcomes. With respect to specific outcomes, the combined ES's for
255 anxiety, depression, dyspnea, and QoL ($g=0.24-0.45$ ($r=0.12-0.22$)) all reached statistical signifi-
256 cance ($p: 0.001-0.047$). The combined ES ($g=0.25$ ($r=0.12$)) for exercise capacity was near-
257 significant ($p=0.069$), whereas the combined ES's for fatigue and lung function did not reach statis-
258 tical significance.

259 ***Associations between ES and study characteristics***

260 As the Q -statistic for both psychological and physical outcomes were statistically significant
261 ($p=0.017$, <0.001) and the I^2 statistic indicated low to moderate heterogeneity, we explored possible
262 sources of heterogeneity and analyzed whether the ES's varied according to between-study differ-
263 ences in study design (active versus passive control), intervention type (CBT versus mind-body),
264 sample characteristics (age; gender; lung function at baseline), intervention length (number of ses-
265 sions; treatment duration) and methodological quality (quality scores).

266 ***Study design***

267 The pooled ES's for the active and passive control group studies are shown in Table 2. With respect
268 to psychological outcomes, the ES's were similar, and the between-group difference did not reach
269 statistical significance. For the physical outcomes, the combined ES was smaller for passive control
270 than active control studies, but again, the between-group difference did not reach statistical signifi-
271 cance.

272 ***Intervention type***

273 The combined ES's of studies examining the effects of CBT and mind-body interventions are
274 shown in Table 2. For psychological outcomes, CBT and mind-body yielded similar ES's ($g=0.39$
275 ($r=0.19$) and $g=0.38$ ($r=0.19$)). However, only CBT reached statistical significance, whereas mind-
276 body interventions were near-significant ($p=0.081$). For physical outcomes, only mind-body inter-
277 ventions yielded a statistical significant ES of $g=0.40$ ($r=0.20$). In comparison, the ES for CBT for
278 physical outcomes was small ($g=0.09$ ($r=0.05$)) and statistically non-significant. The difference
279 between the effects of CBT versus mind-body interventions, however, did not reach statistical sig-
280 nificance. Insufficient power for tests of moderation is a well-known problem in meta-analysis [38].
281 Following the suggestions of Hedges & Pigott [38], we therefore conducted a post-hoc power anal-
282 ysis, revealing a statistical power of the between-group comparison of CBT and mind-body inter-
283 ventions for physical outcomes of only 0.30.

284 As only mind-body interventions appeared to be effective for the combined physical outcomes, the
285 effects of mind-body intervention for each of the individual physical outcomes were analyzed. A
286 statistically significant effect of mind-body intervention was found for dyspnea ($g=0.38$ ($K=7$) (CI:
287 $0.04-0.71$, $p=0.028$). The remaining effect sizes did not reach statistical significance ($g= -0.02-0.33$;
288 $K=3-6$; $p=0.146-0.951$). No effects of CBT were found for any of the individual physical outcomes
289 (no further data shown). When comparing effect sizes between mind-body therapies and CBT for
290 the individual physical outcomes, mind-body therapies yielded larger effect sizes than CBT for
291 dyspnea ($g=0.38$ vs. 0.01), lung function (0.15 vs. -0.24), and exercise capacity (0.33 vs. 0.08),
292 whereas the results for fatigue appeared to favor CBT (-0.02 vs. 0.26). None of the differences
293 reached statistical significance, however (no further data shown).

294 *Sample characteristics, intervention length and study quality*

295 As shown in [Table 3](#), we conducted two meta-regression analyses (unrestricted maximum likeli-
296 hood) with the Jadad quality score, the Jadad-revised quality score, treatment duration, number of
297 sessions, mean age, percent women, and mean FEV1% pred. as the predictor variables and ES's for
298 the combined psychological and physical outcome categories as dependent variables. In both anal-
299 yses, only treatment duration reached near-significance (psychological: $p=0.054$; physical:
300 $p=0.066$), with negative regression slopes (psychological: $B=-0.06$; physical: $B=-0.05$) indicating
301 that longer treatment duration was associated with smaller ES's for psychological and physical out-
302 comes. Furthermore we compared the average duration and number of sessions of CBT and mind-
303 body interventions. The results indicated that mind-body intervention had longer duration (7.2 wks
304 ($SD: 3.9$)) and included more sessions (18.8 (20.0)) than CBT (6.0 (3.0) and 10.5 (16.0)). However,
305 the differences did not reach statistical significance ($p=0.41$ and 0.25).

306 **DISCUSSION**

307 The results initially revealed statistically significant effects of psychosocial interventions on both
308 psychological ($g=0.39$ ($r=0.19$)) and physical ($g=0.30$ ($r=0.15$)) outcomes in COPD patients when
309 compared with passive (care as usual) or active control groups. The effect size for psychological
310 outcomes remained relatively stable and statistically significant after adjusting for possible publica-
311 tion bias, whereas the effect size for physical outcomes was reduced ($g=0.20$ ($r=0.10$)) and became
312 only near-significant. Our findings are in contrast to the results of another relatively recent meta-
313 analysis by Baraniak and Sheffield [15], where only anxiety was improved by psychologically-
314 based interventions in COPD. A possible explanation for the inconsistent findings could be that the
315 quantity of published research in the area has grown over the years since Baraniak and Sheffield
316 conducted their review. Thus, coupled with the fact that we also included psychosocial mind-body
317 interventions, the results of the present study were based on data from a larger combined sample of
318 COPD-patients. Also, in the present study, we have statistically adjusted for possible publication
319 bias, which Baraniak and Sheffield reckoned was a problem for the interpretation of their results,
320 thereby giving way for a more precise effect size estimate.

321 As the construct of QoL is a multifaceted and relatively incongruently defined construct [39], we
322 found it inappropriate to include it in either the psychological or the physical overall outcome cate-
323 gory. The results revealed a statistically significant, but small, effect on QoL, giving further support
324 to the notion that psychosocial intervention may improve outcomes that involve both the psycholog-
325 ical and the physical domain of COPD. However, researchers conducting future meta-analyses
326 should be aware of the possible pitfalls of combining data from studies defining QoL differently.

327 Regarding the effects of the different types of psychosocial intervention being used with COPD
328 patients, the moderation analyses showed that only CBT, but not mind-body interventions, signifi-
329 cantly improved psychological outcomes. For the physical outcomes, the opposite result was found.
330 Here, only the results for mind-body interventions reached statistical significance. When exploring

331 effects on the individual types of physical outcomes, mind-body interventions had larger, albeit
332 non-significant, effects on dyspnea, exercise capacity, and lung function, whereas the effect on fa-
333 tigue was non-significant in the opposite direction. Our findings could be interpreted as supporting
334 previous speculations [15,40] that ruminative thinking and avoidance, the primary focus of CBT,
335 are often associated with the characteristic and noteworthy physical symptoms in COPD. Conse-
336 quently, subjecting symptoms such as dyspnea to the exposure techniques often used in CBT could
337 in the best case be ineffective and, in the worst case, harmful. In contrast, mind-body interventions
338 explicitly take into account the co-influencing aspects of physical and psychological issues in
339 COPD and hold a primary focus on physical sensations, rather than on psychological, i.e. cognitive
340 and emotional, processes, as the therapeutic gateway towards change [41]. However, it should here
341 be noted that the precision of the estimated effect sizes of interventions types in the present study
342 may be limited, as indicated by the relatively broad confidence intervals. In addition, the results of
343 our post-hoc power analysis suggest that more studies are needed to confirm this preliminary con-
344 clusion.

345 With the purpose of minimizing costs, psychosocial interventions are often delivered alongside oth-
346 er behavioral treatment initiatives such as pulmonary rehabilitation programs (most often including
347 health education and physical exercise). Exploring directly whether this mode of delivery influences
348 the effect of the psychosocial interventions lay outside the scope of the present study. However, the
349 results failed to find any difference in ES's between the studies that included an active control
350 group and those that did not (passive control group). This could indicate that receiving other behav-
351 ioral treatments (e.g. disease-specific or general health education, breathing and walking exercise,
352 and support groups) simultaneously does not compromise the effect of psychosocial intervention.
353 On the other hand, whether psychosocial intervention moderates, e.g. boosts or reduces, the effects
354 of other behavioral and medical treatment regimens still needs to be explored.

355 Surprisingly, the near-significant results of our meta-regression analysis indicated that overall, irre-
356 spective of the type of intervention, longer treatment duration may reduce the effect of psychologi-
357 cal intervention. One possible explanation for this inverse relationship could be the natural deterio-
358 ration of the chronic patients' psychological and physical condition over time – especially prevalent
359 for smokers [42]. Another explanation could be the tedium of longer interventions or overstimula-
360 tion, which are long-discussed challenges in the psychotherapy process [43,44]. However as a third
361 possible explanation, the lesser effects of longer interventions could also be due to the relatively
362 longer follow-up time, which might cause a loss of novelty and regression toward the mean. The
363 finding that longer duration was associated with smaller, rather than larger, ES's, also suggest that
364 the – non-significant – finding of longer duration of mind-body interventions compared to CBT's,
365 does not explain the larger ES's found for physical outcomes for mind-body interventions compared
366 to CBT. Further studies are needed to identify the optimal type and duration of psychosocial inter-
367 ventions for various outcomes in COPD.

368 The present study is the first to quantify the effect of psychosocial interventions on psychological as
369 well as physical outcomes in COPD. It has several strengths in that it is based on rigorous methodo-
370 logical procedures and instruments (i.e. protocol-based inclusion with two independent reviewers,
371 comprehensive methodological quality ratings and adjustment for publication bias) and includes
372 only controlled studies, which substantially increases the likelihood that changes in post-
373 intervention scores can be attributed to the intervention and not to other potentially confounding
374 variables. Moreover, the present study includes mind-body interventions, which have generally
375 been ignored in reviews of psychological intervention in COPD so far, even though they form a
376 type of psychosocial intervention that has become a subject of increased popularity and evidence in
377 healthcare research literature over the last few decades [41]. Among the limitations are that the
378 available data do not allow for any conclusions as to the long-term maintenance of the effect, as the

majority of included studies did not present follow-up data in their analysis. Furthermore, not all included studies reported data on each outcome category of interest and the instruments used to measure psychological and physical outcomes were diverse. This was also the case for QoL instruments, with some studies using disease-specific and others using generic outcome measures.

CONCLUSIONS

The results of this methodologically thorough systematic review and meta-analysis suggest that psychosocial interventions, including physically oriented mind-body interventions, have the potential for improving both psychological and physical outcomes in COPD. It should be noted, however, that our findings of possible publication bias towards studies reporting larger and positive effect sizes may question the robustness of the effect found for physical outcomes. Despite this cautionary note, based on the overall results, it appears appropriate to recommend delivering psychosocial intervention alongside the already established medical treatment pathway. Concerning specific types of psychosocial intervention, clinicians could consider offering CBT if the primary purpose is to relieve psychological health outcomes, and mind-body interventions with the primary purpose of relieving physical health outcomes. However, clinicians, researchers, and policy makers should be aware that, due to statistical power issues and the possible tendency towards publishing positive and significant findings, the robustness of the results presented here cannot be fully ensured and should therefore be interpreted with some caution.

CONFLICT OF INTEREST

The authors declare that they have no conflict of interest.

401 **REFERENCES**

- 402 1. Rycroft CE, Heyes A, Lanza L, Becker K: Epidemiology of chronic obstructive pulmonary
403 disease: A literature review. *Int J COPD* 2012;7:457–494.
- 404 2. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C,
405 Rodriguez-Roisin R, van Weel C, Zielinski J: Global strategy for the diagnosis, management, and
406 prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit*
407 *Care Med* 2007;176:532–555.
- 408 3. Agustí AGN: Systemic effects of chronic obstructive pulmonary disease. *Proc Am Thorac Soc*
409 2005;2:367–370.
- 410 4. Hynninen KMJ, Breivte MH, Wiborg AB, Pallesen S, Nordhus IH: Psychological characteristics
411 of patients with chronic obstructive pulmonary disease: A review. *J Psychosom Res* 2005;59:429–
412 443.
- 413 5. Laurin C, Moullec G, Bacon SL, Lavoie KL: The impact of psychological distress on
414 exacerbation rates in COPD. *Ther Adv Respir Dis* 2011;5:3–18.
- 415 6. Yohannes AM, Baldwin RC, Connolly MJ: Depression and anxiety in elderly patients with
416 chronic obstructive pulmonary disease. *Age Ageing* 2006;35:457–459.
- 417 7. Cafarella PA, Effing TW, Usmani Z-A, Frith PA: Treatments for anxiety and depression in
418 patients with chronic obstructive pulmonary disease: A literature review. *Respirology* 2012;17:627–
419 638.
- 420 8. Anderson KL: The effect of chronic obstructive pulmonary disease on quality of life. *Res Nurs*
421 *Health* 1995;18:547–556.
- 422 9. Breslin E, van der Schans C, Breukink S, Meek P, Mercer K, Volz W, Louie S: Perception of
423 fatigue and quality of life in patients with COPD. *Chest* 1998;114:958–964.
- 424 10. Borge CR, Wahl AK, Moum T: Association of breathlessness with multiple symptoms in
425 chronic obstructive pulmonary disease. *J Adv Nurs* 2010;66:2688–2700.
- 426 11. Bailey PH: The dyspnea-anxiety-dyspnea cycle--COPD patients' stories of breathlessness: "It's
427 scary /when you can't breathe." *Qual Health Res* 2004;14:760–778.
- 428 12. de Voogd JN, Sanderman R, Postema K, van Sonderen E, Wempe JB: Relationship between
429 anxiety and dyspnea on exertion in patients with chronic obstructive pulmonary disease. *Anxiety*
430 *Stress Copin* 2011;24:439–449.
- 431 13. Rose C, Wallace L, Dickson R, Ayres J, Lehman R, Searle Y, Burge PS: The most effective
432 psychologically-based treatments to reduce anxiety and panic in patients with chronic obstructive
433 pulmonary disease (COPD): A systematic review. *Patient Educ Couns* 2002;47:311–318.

- 434 14. Coventry PA, Gellatly JL: Improving outcomes for COPD patients with mild-to-moderate
435 anxiety and depression: A systematic review of cognitive behavioural therapy. *Brit J Health Psych*
436 2008;13:381–400.
- 437 15. Baraniak A, Sheffield D: The efficacy of psychologically based interventions to improve
438 anxiety, depression and quality of life in COPD: A systematic review and meta-analysis. *Patient*
439 *Educ Couns* 2011;83:29–36.
- 440 16. Clark NM, Dodge JA, Partridge MR, Martinez FJ: Focusing on outcomes: Making the most of
441 COPD interventions. *Int J COPD* 2009;4:61–77.
- 442 17. Dobson KS (ed): *Handbook of cognitive-behavioral therapies*. New York, The Guilford Press,
443 2010.
- 444 18. Barrows KA, Jacobs BP: Mind-body medicine: An introduction and review of the literature.
445 *Med Clin North Am* 2002;86:11–31.
- 446 19. Sackett DL, Richardson WS, Rosenberg W, Haynes RB: *Evidence-based medicine: How to*
447 *practice and teach EBM*. New York, Churchill Livingstone, 1997.
- 448 20. Moher D, Liberati A, Tetzlaff J, Altman DG: Preferred reporting items for systematic reviews
449 and meta-analyses: The PRISMA statement. *J Clin Epidemiol* 2009;62:1006–1012.
- 450 21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJM, Gavaghan DJ, McQuay HJ:
451 Assessing the quality of reports of randomized clinical trials: Is blinding necessary? *Control Clin*
452 *Trials* 1996;17:1–12.
- 453 22. Greenland S, O'Rourke K: On the bias produced by quality scores in meta-analysis, and a
454 hierarchical view of proposed solutions. *Biostatistics* 2001;2:463–471.
- 455 23. Sterne JAC, Egger M, Moher D: Addressing reporting biases; in Higgins JPT, Green S (eds):
456 *Cochrane Handbook for Systematic Reviews of Intervention*. ed 5.0.1. The Cochrane Collaboration,
457 2008.
- 458 24. Poole C, Greenland S: Random-effects meta-analyses are not always conservative. *Am J*
459 *Epidemiol* 1999;150:469–475.
- 460 25. Higgins JPT, Thompson SG, Deeks JJ, Altman DG: Measuring inconsistency in meta-analyses.
461 *BMJ* 2003;327:557–560.
- 462 26. Cohen J: *Statistical power analysis for the behavioral sciences*, ed 2. Hillsdale, Lawrence
463 Erlbaum, 1988.
- 464 27. Hedges L, Olkin I: *Statistical methods for meta-analysis*. New York, Academic Press, 1985.
- 465 28. Ioannidis JPA, Trikalinos TA: The appropriateness of asymmetry tests for publication bias in
466 meta-analyses: A large survey. *Can Med Assoc J* 2007;176:1091–1096.

- 467 29. Copas J, Shi JQ: Meta-analysis, funnel plots and sensitivity analysis. *Biostatistics* 2000;1:247–
468 262.
- 469 30. Deeks JJ, Macaskill P, Irwig L: The performance of tests of publication bias and other sample
470 size effects in systematic reviews of diagnostic test accuracy was assessed. *J Clin Epidemiol*
471 2005;58:882–893.
- 472 31. Egger M, Smith GD, Schneider M, Minder C: Bias in meta-analysis detected by a simple,
473 graphical test. *BMJ* 1997;315:629–634.
- 474 32. Rosenthal R: The file drawer problem and tolerance for null results. *Psychol Bull* 1979;86:638–
475 641.
- 476 33. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting
477 for publication bias in meta-analysis. *Biometrics* 2000;56:455–463.
- 478 34. Emery CF, Schein RL, Hauck ER, MacIntyre NR: Psychological and cognitive outcomes of a
479 randomized trial of exercise among patients with chronic obstructive pulmonary disease. *Health*
480 *Psychol* 1998;17:232–240.
- 481 35. de Godoy DV, de Godoy RF, Becker B, Vaccari PF, Michelli M, Teixeira PJZ, Palombini BC:
482 The effect of psychotherapy provided as part of a pulmonary rehabilitation program for the
483 treatment of patients with chronic obstructive pulmonary disease. *J Bras Pneumol* 2005;31:499–
484 505.
- 485 36. Rosser R, Denford J, Heslop A, Kinston W, Macklin D, Minty K, Moynihan C, Muir B, Rein L,
486 Guz A: Breathlessness and psychiatric morbidity in chronic bronchitis and emphysema: A study of
487 psychotherapeutic management. *Psychol Med* 1983;13:93–110.
- 488 37. Chan AWK, Lee A, Suen LKP, Tam WWS: Tai chi Qigong improves lung functions and
489 activity tolerance in COPD clients: A single blind, randomized controlled trial. *Complement Ther*
490 *Med* 2011;19:3–11.
- 491 38. Hedges LV, Pigott TD: The power of statistical tests for moderators in meta-analysis. *Psychol*
492 *Methods* 2004;9:426–445.
- 493 39. Jones P, Miravittles M, van der Molen T, Kulich K: Beyond FEV1 in COPD: A review of
494 patient-reported outcomes and their measurement. *Int J COPD* 2012;7:697–709.
- 495 40. Coventry PA, Bower P, Keyworth C, Kenning C, Knopp J, Garrett C, Hind D, Malpass A,
496 Dickens C: The effect of complex interventions on depression and anxiety in chronic obstructive
497 pulmonary disease: Systematic review and meta-analysis. *PLOS ONE* 2013;8:e60532.
- 498 41. Barrows KA, Jacobs BP: Mind-body medicine: An introduction and review of the literature.
499 *Med Clin North Am* 2002;86:11–31.
- 500 42. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, Carrozzi L: Definition, epidemiology and
501 natural history of COPD. *Eur Respir J* 2007;30:993–1013.

502 43. Lieberman MA, Yalom ID, Miles MB: Encounter groups: First facts. New York, Basic Books,
503 1973.

504 44. Doxsee DJ, Kivlighan DM: Hindering events in interpersonal relations groups for counselor
505 trainees. *J Couns Dev* 1994;72:621–626.

506 45. Gift AG, Moore T, Soeken K: Relaxation to reduce dyspnea and anxiety in COPD patients.
507 *Nurs Res* 1992;41:242–246.

508 46. Sassi-Dambron DE, Eakin EG, Ries AL, Kaplan RM: Treatment of dyspnea in COPD: A
509 controlled clinical trial of dyspnea management strategies. *Chest* 1995;107:724–729.

510 47. Eiser N, West C, Evans S, Jeffers A, Quirk F: Effects of psychotherapy in moderately severe
511 COPD: A pilot study. *Eur Respir J* 1997;10:1581–1584.

512 48. Kunik ME, Braun U, Stanley MA., Wristers K, Molinari V, Stoeber D, Orengo CA: One
513 session cognitive behavioural therapy for elderly patients with chronic obstructive pulmonary
514 disease. *Psychol Med* 2001;31:717–723.

515 49. Kheirabadi GR, Keypour M, Attaran N, Bagherian R, Peza M: Effect of add-on “Self
516 Management and Behavior Modification ” education on severity of COPD. *Tanaffos* 2008;7:23–30.

517 50. Kunik ME, Veazey C, Cully JA, Soucek J, Graham DP, Hopko D, Carter R, Sharafkhaneh A,
518 Goepfert EJ, Wray N, Stanley MA: COPD education and cognitive behavioral therapy group
519 treatment for clinically significant symptoms of depression and anxiety in COPD patients: A
520 randomized controlled trial. *Psychol Med* 2008;38:385–396.

521 51. Donesky-Cuenca D, Nguyen HQ, Paul S, Carrieri-Kohlman V: Yoga therapy decreases
522 dyspnea-related distress and improves functional performance in people with chronic obstructive
523 pulmonary disease: A pilot study. *J Altern Complem Med* 2009;15:225–234.

524 52. Mularski RA, Munjas BA, Lorenz KA, Sun S, Robertson SJ, Schmelzer W, Kim AC, Shekelle
525 PG: Randomized controlled trial of mindfulness-based therapy for dyspnea in chronic obstructive
526 lung disease. *J Altern Complem Med* 2009;15:1083–1090.

527 53. Singh VP, Rao V, Prem V, Sahoo RC, Keshav Pai K: Comparison of the effectiveness of music
528 and progressive muscle relaxation for anxiety in COPD: A randomized controlled pilot study.
529 *Chron Respir Dis* 2009;6:209–216.

530 54. Hynninen MJ, Bjerke N, Pallesen S, Bakke PS, Nordhus IH: A randomized controlled trial of
531 cognitive behavioral therapy for anxiety and depression in COPD. *Respir Med* 2010;104:986–994.

532 55. Lamers F, Jonkers CCM, Bosma H, Chavannes NH, Knottnerus JA, van Eijk JT: Improving
533 quality of life in depressed COPD patients: Effectiveness of a minimal psychological intervention.
534 *COPD* 2010;7:315–322.

535 56. Livermore N, Sharpe L, McKenzie D: Prevention of panic attacks and panic disorder in COPD.
536 *Eur Respir J* 2010;35:557–563.

- 537 57. Yeh GY, Roberts DH, Wayne PM, Davis RB, Quilty MT, Phillips RS: Tai chi exercise for
538 patients with chronic obstructive pulmonary disease: A pilot study. *Respir Care* 2010;55:1475–
539 1482.
- 540 58. Kapella MC, Herdegen JJ, Perlis ML, Shaver JL, Larson JL, Law JA, Carley DW: Cognitive
541 behavioral therapy for insomnia comorbid with COPD is feasible with preliminary evidence of
542 positive sleep and fatigue effects. *Int J COPD* 2011;6:625–635.
- 543 59. Ng BHP, Tsang HWH, Jones AYM, So CT, Mok TYW: Functional and psychosocial effects of
544 health qigong in patients with COPD: A randomized controlled trial. *J Altern Complem Med*
545 2011;17:243–251.
- 546 60. Jiang X, He G: Effects of an uncertainty management intervention on uncertainty, anxiety,
547 depression, and quality of life of chronic obstructive pulmonary disease outpatients. *Res Nurs*
548 *Health* 2012;35:409–418.
- 549 61. American Thoracic Society: ATS Statement: Guidelines for the six-minute walk test. *Am J*
550 *Respir Crit Care Med* 2002;166:111–117.
- 551 62. Borg GAV: Psychophysical bases of perceived exertion. *Med Sci Sports Exerc* 1982;14:377–
552 381.
- 553 63. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW: A measure of quality of life
554 for clinical trials in chronic lung disease. *Thorax* 1987;42:773–778.
- 555 64. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, Sobel K,
556 Coyle N, Kemeny N, Norton L, Scher H: The Memorial Symptom Assessment Scale: An
557 instrument for the evaluation of symptom prevalence, characteristics and distress. *Eur J Cancer*
558 1994;30A:1326–1336.
- 559 65. Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ: The Pittsburgh Sleep Quality
560 Index: A new instrument for psychiatric practice and research. *Psychiat Res* 1989;28:193–213.
- 561 66. Qaseem A, Wilt TJ, Weinberger SE, Hanania NA, Criner G, van der Molen T, Marciniuk DD,
562 Denberg T, Schünemann H, Wedzicha W, MacDonald R, Shekelle P: Diagnosis and management
563 of stable chronic obstructive pulmonary disease: A clinical practice guideline update from the
564 American College of Physicians, American College of Chest Physicians, American Thoracic
565 Society, and European Respiratory Society. *Ann Intern Med* 2011;155:179–192.
- 566 67. Gift AG: Visual analogue scales: Measurement of subjective phenomena. *Nurs Res*
567 1989;38:286–288.
- 568 68. Beck AT, Steer RA: Beck Anxiety Inventory manual. San Antonio, The Psychological
569 Corporation, Harcourt Brace & Co., 1993.
- 570 69. Beck AT, Ward CH, Mendelsohn M, Mock J, Erbaugh J: An inventory for measuring
571 depression. *Arch Gen Psychiat* 1961;4:561–571.

- 572 70. Radloff LS: The CES-D scale: A self-report depression scale for research in the general
573 population. *Appl Psych Meas* 1977;1:385–401.
- 574 71. Stiles PG, McGarrahan JF: The Geriatric Depression Scale: A comprehensive review. *J Clin*
575 *Geropsychol* 1998;4:89–110.
- 576 72. Zigmond AS, Snaith RP: The Hospital Anxiety And Depression Scale. *Acta Psychiat Scand*
577 1983;67:570–579.
- 578 73. McNair D, Lorr M, Droppleman M: The Profile of Mood States. San Diego, CA, Educational
579 and Industrial Testing Service, 1992.
- 580 74. Spielberger L: STAI manual. Palo Alto, Psychologists Consultants Press, 1983.
- 581 75. Derogatis LR: Symptom checklist-90 manual. Baltimore, Johns Hopkins University Press,
582 1977.
- 583 76. van der Molen T, Willemse BWM, Schokker S, ten Hacken NHT, Postma DS, Juniper EF:
584 Development, validity and responsiveness of the Clinical COPD Questionnaire. *Health Qual Life*
585 *Outcomes* 2003;1:13.
- 586 77. Leidy NK: Psychometric properties of the functional performance inventory in patients with
587 chronic obstructive pulmonary disease. *Nurs Res* 1999;48:20–28.
- 588 78. Ware JE: SF-36 Health Survey: Manual & interpretation guide. Boston, The Health Institute,
589 New England Medical Center, 1993.
- 590 79. Meguro M, Barley EA, Spencer S, Jones PW: Development and validation of an improved,
591 COPD-specific version of the St. George Respiratory Questionnaire. *Chest* 2007;132:456–463.
- 592 80. Bergner M, Bobbitt RA, Carter WB, Gilson BS: The Sickness Impact Profile: Development and
593 final revision of a health status measure. *Med Care* 1981;19:787–805.
- 594 81. Kaplan RM, Anderson JP: The quality of well-being scale: Rationale for a single quality of life
595 index; in Walker SR, Rosser RM (eds): *Quality of life: Assessment and application*. London, MTP
596 Press; 1988, pp 51–77.

597

I. Farver-Vestergaard, D. Jacobsen, R. Zachariae: Efficacy of psychosocial interventions on psychological and physical health outcomes in chronic obstructive pulmonary disease (COPD): A systematic review and meta-analysis.

Figures and tables

Figure 1. PRISMA flow-chart of study selection procedure

Figure 2. Combined effect sizes (Hedges g; random effect model) of psychosocial interventions on a) psychological, b) physical, and c) quality of life outcomes in studies of COPD-patients.

Table 1. Study characteristics

Table 2. Effects of psychological intervention on psychological and physical outcomes in COPD patients.

Table 3. Moderation analyses: Results of meta-regression analyses

Figure 1. PRISMA Flow-chart of selection procedure

a) Psychological outcomes

b) Physical outcomes

c) Quality of Life (QoL) outcomes

Table 1. Study characteristics

Author	Year	Study design ^a	N (N) ^b COPD severity at baseline (mean or proportion)	Mean age % women	Groups ^c (N assigned (N in final analysis))	Intervention type (category) ^d	No. of sessions (Treatment duration (weeks))	Physical outcome measure(s) ^e	Psychological outcome measure(s) ^f	Quality of life outcome measure ^g	Jadad quality score, range: 0-13) ^h	Jadad-revised quality score, range: 0-18) ⁱ
1. Rosser et al. [36]	1983	RCT	65 (22) -	66 yrs. 33.8	1) PC (17(12)) 2) Analytic psychotherapy(16(10))	Analytic	8 (8)	1) Lung function: Spirometry	-	-	9	12
2. Gift et al. [45]	1992	RCT	26 (26) Mean: 54.0	67 yrs. 69.2	1) AC (relaxation without guiding) (13(13)) 2) Guided relaxation (13(13))	Mind-body	4 (4)	1) Lung function: Wright Peak Flow Meter 2) Dyspnea: VAS	1) Anxiety: SAI	-	6	9
3. Sassi-Dambron et al. [46]	1995	RCT	98 (89) Mean: 50.0	67.4 yrs. 44.9	1) AC (health education) (51(43)) 2) Health education, relaxation and stress management (47(46))	Mind-body	6 (6)	1) Dyspnea: VAS 2) Exercise capacity: 6MWT	1) Anxiety: SAI 2) Depression: CES-D	QWB	9	12
4. Eiser et al. [47]	1997	NRCT	20 (20) Prop.: 100% severe	72.2 yrs. 60.0	1) PC (8(8)) 2) CBT (12(12))	CBT	6 (6)	1) Lung function: Spirometry 2) Dyspnea: VAS 3) Exercise capacity: 6MWT	-	SGRQ	5	7
5. Emery et al. [34]	1998	RCT	79 (48) Mean: 42.0	66.6 yrs. 53.2	1) PC (25(25)) 2) Stress management, CBT format (25(23))	CBT	63 (10)	1) Lung function: Spirometry	1) Anxiety: SAI 2) Depression: CES-D	SIP	9	11
6. Kunik et al. [48]	2001	RCT	56 (48) -	71.3 yrs. 17.0	1) AC (COPD education) (29(27)) 2) CBT (24(21))	CBT	1 (1)	1) Exercise capacity: 6MWT	1) Anxiety: BAI 2) Depression: GDS	SF-36	10	14

Author	Year	Study design ^a	N (N) ^b COPD severity at baseline (mean or proportion)	Mean age % women	Groups ^c (N assigned (N in final analysis))	Intervention type (category) ^d	No. of sessions (Treatment duration (weeks))	Physical outcome measure(s) ^e	Psychological outcome measure(s) ^f	Quality of life outcome measure ^g	Jadad quality score, range: 0-13) ^h	Jadad-revised quality score, range: 0-18) ⁱ
7. de Godoy et al. [35]	2005	RCT	49 (30) Mean: 34.0	- 27.0	1) PC (14(14)) 2) CBT and logotherapy techniques (16(16))	CBT	24 (12)	1) Exercise capacity: Distance walked-weight product	1) Anxiety: BAI 2) Depression: BDI	SGRQ	7	10
8. Kheirabadi et al. [49]	2008	RCT	42 (42) -	56.4 yrs. 31.0	1) PC (21(21)) 2) Psychoeducation and behaviour therapy (21(21))	Behavioral	8 (8)	1) Lung function: CCQ- symptoms subscale	-	CCQ	7	9
9. Kunik et al. [50]	2008	RCT	238 (235) Mean: 46.0	66.3 yrs. 3.8	1) AC (COPD education) (120(119)) 2) CBT (118(116))	CBT	8 (8)	1) Dyspnea: CRQ-Dyspnea subscale 2) Exercise capacity: 6MWT 3) Fatigue: CRQ-Fatigue subscale	1) Anxiety: BAI 2) Depression: BDI	SF-36	10	13
10. Donesky-Cuenca et al. [51]	2009	RCT	41 (29) Mean: 47.7	69.9 yrs. 72.4	1) PC (21(15)) 2) Yoga-meditation (20(14))	Mind-body	24 (12)	1) Dyspnea: CRQ-Dyspnea subscale 2) Lung function: Spirometry 3) Exercise capacity: 6MWT 4) Fatigue: CRQ-Fatigue subscale	1) Anxiety: SAI-State subscale 2) Depression: CES-D	SF-36	9	11
11. Mularski et al. [52]	2009	RCT	86 (86) Prop.: 64% severe	67.4 yrs. 0.0	1) AC (support groups) (42(42)) 2) Mindfulness-based breathing therapy (44(44))	Mind-body	8 (8)	1) Lung function: MSAS 2) Dyspnea: VAS 3) Exercise capacity: 6MWT	-	SGRQ	10	13

Author	Year	Study design ^a	N (N) ^b COPD severity at baseline (mean or proportion)	Mean age % women	Groups ^c (N assigned (N in final analysis))	Intervention type (category) ^d	No. of sessions (Treatment duration (weeks))	Physical outcome measure(s) ^e	Psychological outcome measure(s) ^f	Quality of life outcome measure ^g	Jadad quality score, range: 0-13) ^h	Jadad-revised quality score, range: 0-18) ⁱ
12. Singh et al. [53]	2009	RCT	72 (64) Mean: 51.5	63.0 yrs. 30.0	1) AC (relaxation without music) (36(32)) 2) Music therapy and relaxation (36(32))	Mind-body	2 (1)	1) Lung function: Respiratory rate 2) Dyspnea: VAS	1) Anxiety: SAI-State subscale	-	9	13
13. Hynninen et al. [54]	2010	RCT	51 (51) Mean: 58.8	61.0 yrs. 51.0	1) PC (26(26)) 2) CBT (25(25))	CBT	7 (7)	1) Fatigue: PSQI	1) Anxiety: BAI 2) Depression: BDI	SGRQ	8	10
14. Lamers et al. [55]	2010	RCT	187 (187) -	71.0 yrs. 40.0	1) PC (91(91)) 2) CBT and self-management elements (96(96))	CBT	4 (12)	-	1) Anxiety: SCL-90 Anxiety subscale 2) Depression: BDI	SGRQ	10	13
15. Livermore et al. [56]	2010	RCT	41 (41) Mean: 54.1	73.4 yrs. 56.1	1) PC (20(20)) 2) CBT (21(21))	CBT	4 (4)	-	1) Anxiety: HADS- Anxiety subscale 2) Depression: HADS- Depression subscale	SGRQ	11	14
16. Yeh et al. [57]	2010	RCT	10 (10) Mean: 50.0	66.0 yrs. 40.0	1) PC (5(5)) 2) Tai chi meditative exercise (5(5))	Mind-body	24 (12)	1) Lung function: Spirometry 2) Dyspnea: CRQ-Dyspnea subscale 3) Exercise capacity: 6MWT 4) Fatigue: CRQ-Fatigue subscale	1) Depression: CES-D	CRQ	10	13

Author	Year	Study design ^a	N (N) ^b COPD severity at baseline (mean or proportion)	Mean age % women	Groups ^c (N assigned (N in final analysis))	Intervention type (category) ^d	No. of sessions (Treatment duration (weeks))	Physical outcome measure(s) ^e	Psychological outcome measure(s) ^f	Quality of life outcome measure ^g	Jadad quality score, range: 0-13) ^h	Jadad-revised quality score, range: 0-18) ⁱ
17. Chan et al. [37]	2011	RCT	206 (139) Prop.: 43% severe	73.0 yrs. 8.7	1) AC (breathing techniques and walking exercise) (69(69)) 2) Tai chi meditative exercise (70(70))	Mind-body	24 (12)	1) Lung function: Spirometry 2) Dyspnea: Borg scale 3) Exercise capacity: 6MWT 4) Fatigue: Borg scale	-	-	10	14
18. Kapella et al. [58]	2011	RCT	18 (18) Mean: 60.5	62.5 yrs. 22.2	1) AC (wellness education) (9(9)) 2) CBT for insomnia (9(9))	CBT	6 (6)	1) Fatigue: PSQI	1) Anxiety: POMS-Anxiety subscale 2) Depression: POMS-Depression subscale	FPI	9	12
19. Ng et al. [59]	2011	RCT	80 (80) Mean: 36.9	72.4 yrs. 11.2	1) AC (breathing techniques and walking exercise) (40(40)) 2) Qigong meditative exercise (40(40))	Mind-body	4 (4)	1) Exercise capacity: 6MWT	-	SF-36	11	15
20. Jiang et al. [60]	2012	RCT	100 (96) Prop.:39% severe	65.0 yrs. 30.2	1) PC (50(47)) 2) Uncertainty management, cognitive and behavioral strategies (50 (49))	CBT	4 (4)	-	1) Anxiety: SAI-State subscale 2) Depression: HADS- Depression subscale	SF-36	11	14

Notes: a) Abbreviations: NRCT (Non-randomized controlled trial), RCT (Randomized controlled trial); b) N (reported total sample size), (N) (Final sample size used in evaluation of effect on outcomes), COPD severity: % predicted forced expiratory volume per second (FEV1% pred.) reported as mean or percentage in the category “severe”; c) Abbreviations: AC (Active

control), CBT (Cognitive-behavioral therapy), PC (Passive control); d) CBT (Cognitive-behavioral therapy), Mind-body (Relaxation, Mindfulness, Meditative yoga, qigong or tai chi); e) Physical outcome measures: 6MWT (Six-Minute Walk Test [61]), Borg scale [62], CRQ (Chronic Respiratory Questionnaire [63]), MSAS (Memorial Symptom Assessment Scale [64]), PSQI (Pittsburgh Sleep Quality Index [65]), Respiratory rate (number of chest wall or abdomen rise and fall movements per minute [53]), Spirometry [66], VAS (Visual Analogue Scale [67]); f) Psychological outcome measures: BAI (Beck Anxiety Inventory [68]), BDI (Beck Depression Inventory [69]), CES-D (Center for Epidemiological Studies Depression scale [70]), GDS (Geriatric Depression Scale [71]), HADS (Hospital Anxiety and Depression Scale [72]), POMS (Profile of Mood States [73]), SAI (Spielberger Anxiety Inventory [74]), SCL-90 (Symptom Checklist-90 [75]), g) Quality of life outcome measures: CCQ (Clinical COPD Questionnaire [76]), CRQ (Chronic Respiratory Questionnaire [63]), FPI (Functional Performance Inventory [77]), SF-36 (the 36-item Short Form Health Survey [78]), SGRQ (Saint George's Respiratory Questionnaire [79]), SIP (Sickness Impact Profile [80]), QWB (Quality of Well-Being scale [81]); h) Jadad study quality score (kilde); i) Total study quality score: modified Jadad score with additional study quality indicators.

Table 2. Effects of psychological intervention on psychological and physical outcomes in COPD patients.

	Sample size		Heterogeneity ^a				Global effect sizes			Failsafe N ^c	Criterion ^d
	K	N	Q	df	<i>p</i>	I ²	Hedges <i>g</i> ^b	95% CI	<i>p</i>		
A. Main effects											
Psychological (anxiety+depression)	14	972	26.0	13	0,017	49,9	0.39	0.19 – 0.58	<0.001	90	80
<i>Psychological adj. for publication bias</i> ^e	(15)	-	-	-	-	-	0.38	0.19 – 0.58	-	-	-
Physical (dyspnea+exercise capacity+fatigue+lung function)	17	1037	42.2	16	<0.001	62.1	0.30	0.08 – 0.52	0.006	64	95
<i>Physical adj. for publication bias</i> ^e	(19)	-	-	-	-	-	0.20	-0.05– 0.44	-	-	-
Anxiety	13	962	46.3	12	<0.000	74.1	0.45	0.18 – 0.72	0.001	108	75
Depression	12	882	13.1	11	0.286	16.2	0.26	0.11 – 0.42	0.001	30	70
Dyspnea	9	698	19.7	8	0.011	59.5	0.27	0.00 – 0.53	0.047	15	55
<i>Dyspnea adj. for publication bias</i> ^e	(10)	-	-	-	-	-	0.20	-0.08– 0.48	-	-	-
Exercise capacity	10	766	26.8	9	0.002	66.4	0.25	-0.02 – 0.52	0.069	-	-
Fatigue	6	482	9.7	5	0.083	48.7	0.13	-0.17 – 0.42	0.411	-	-
Lung function	10	486	19.9	9	0.018	54.9	0.14	-0.14 – 0.43	0.320	-	-
Quality of Life (QoL)	16	1110	34.3	15	0.003	56.3	0.24	0.04 – 0.43	0.018	42	90
B. Moderation analysis: Active versus passive control											
Psychological (active control)	6	480	9.5	5	0.092	47.1	0.37	0.09 – 0.65	0.010	15	40
Psychological (passive control)	8	492	16.2	7	0.023	56.8	0.39	0.09 – 0.69	0.010	24	50
<i>Between groups</i> ^f	14	972	0.09	1	0.928	-	-	-	-	-	-
Physical (active control)	9	785	35.3	8	0.001	77.3	0.37	0.05 – 0.69	0.022	35	55
Physical (passive control)	8	252	6.8	7	0.446	0.0	0.20	-0.04 – 0.45	0.105	-	50
<i>Between groups</i> ^f	17	1037	0.70	1	0.404	-	-	-	-	-	-

C.Moderation analysis: Intervention type (CBT vs. Mind-Body)											
Psychological (CBT)	9	754	17.2	8	0.028	53.6	0.39	0.15 – 0.62	0.001	43	55
Psychological (Mind-Body)	5	218	8.7	4	0.070	53.8	0.38	-0.05 – 0.81	<i>0.081</i>	-	-
<i>Between groups</i> ^f	14	972	0.0	1	0.971	-	-	-	-	-	-
Physical (CBT)	7	450	4.9	6	0.552	0.0	0.09	-0.10 – 0.27	0.345	-	45
Physical (Mind-Body)	8	523	30.4	7	0.001	77.0	0.40	0.01 – 0.79	0.042	26	50
<i>Between groups</i> ^f	15	973	2.0	1	0.153	-	-	-	-	-	-

Notes: a) Q-statistic: p -values < 0.1 taken to suggest heterogeneity. I^2 statistic: 0% (no heterogeneity), 25% (low heterogeneity), 50% (moderate heterogeneity), 75% (high heterogeneity); b) ES = Hedges g . Standardized mean difference, adjusting for small sample bias. A positive value indicates an effect size in the hypothesized direction, i.e. reduced distress or relative smaller increase in distress in the intervention group. To ensure independency, if a study reported results for more than one measure, the ES's were combined (mean), ensuring that only one ES per study was used in the calculation; c) Failsafe N = number of non-significant studies that would bring the p -value to non-significant ($p > 0.05$); d) A Failsafe N exceeding the criterion ($5 \times k + 10$) indicates a robust result [32]; e) If analyses indicated the possibility of publication bias, missing studies were imputed and an adjusted ESR calculated (italics) [33]. (K) indicates number of published studies + number of imputed studies; f) Meta-ANOVA (between-study comparisons)

Table 3. Moderation analyses: Results of meta-regression analyses

Dependent variable	Independent variable	K	Beta ^a	95% CI	p
Psychological (anxiety + depression)	Study quality (Jadad)	13	-0.10	-0.26 – 0.06	0.219
	Study quality (Revised Jadad)	13	-0.05	-0.70 – 2.59	0.491
	Treatment duration	13	-0.06	-0.12 – 0.00	<i>0.054 ^b</i>
	Number of sessions	13	-0.00	-0.02 – 0.01	0.552
	Mean age	12	-0.03	-0.08 – 0.02	0.197
	Percent women	13	0.00	-0.01 – 0.01	0.873
	Mean FEV1%	10	0.01	-0.02 – 0.04	0.576
Physical (dyspnea + exercise capacity + fatigue + lung function)	Study quality (Jadad)	16	0.00	-0.15 – 0.15	0.972
	Study quality (Revised Jadad)	16	0.03	-0.09 – 0.14	0.655
	Treatment duration	16	-0.05	-0.11 – 0.00	<i>0.066 ^c</i>
	Number of sessions	16	-0.01	-0.02 – 0.00	0.114
	Mean age	15	-0.02	-0.07 – 0.03	0.364
	Percent women	16	0.00	-0.01 – 0.01	0.819
	Mean FEV1%	10	0.01	-0.04 – 0.05	0.754

Notes: a) Mixed effects regression: unrestricted maximum likelihood; b) Near-significant ($p < 0.10$) in italics.